The relationship between incarceration and opioid addiction treatment

Slides:



Advertisements
Similar presentations
13 Principles of Effective Addictions Treatment
Advertisements

COMPASS: COMMUNITY PARTNERSHIPS AND SOCIAL SERVICES FOR PEOPLE LIVING WITH HIV LEAVING THE JAIL SETTING Emily Patry, BS The Miriam Hospital, Providence,
Chronically Medically Ill Homeless Women: Characteristics at Baseline Romina Kee MD, MPH Collaborative Research Unit John H. Stroger Hospital CRU.
Differences in Characteristics of Heroin Inhalers and Injectors at Admission to Treatment J. C. Maxwell, R. T. Spence, & T. M. Bohman UT Center for Social.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
UCLA Drug Abuse Research CenterForever Free Evaluation Forever Free Substance Abuse Treatment Program Outcomes Study Michael Prendergast, Ph.D., Principal.
The Effect of Opioid Agonist Maintenance Therapy on Healthcare Utilization and Engagement among HIV-infected People Who Inject Drugs in.
Wei Hao, MD. Mental Health Institute WHO Collaborating Center for Drug Abuse and Health Central South University Prevalence Rates and Related Factors of.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
OPIOID SUBSTITUTION THERAPY
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
Unhealthy alcohol use in other drug users identified by screening in primary care Secondary analysis of ASPIRE trial data Funded by NIDA 1 R01 DA
Farrokh Alemi, Ph.D., Mary Haack, Ph.D., Susie Nemes, Ph.D., Angela Harge, M.Ed., Heibatollah Baghi, Ph.D. This research was supported by a grant from.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
Vivitrol (Naltrexone) Treatment for opioid addiction.
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
Medication Assisted Treatment for Opioid Use Disorders
PURPOSE BACKGROUND RESULTS STUDY DESIGN & METHODS HIV Risk Behaviors Among Male Prisoners Participating in a Randomized Clinical Trial of Methadone Maintenance.
Outcomes Measures for Sexual Minority Patients in an Opioid Treatment Program C. John-Hull, S. Kritz, M. Chu, C. Madray, G. Dominguez, C. Bowers, R. Sumpter,
Justice Health Justice Health and Opioid Substitution The Justice Response Presenters:Larissa Strong, Director Justice Health Scott Drummond, Senior Policy.
Current Mental Health Care Systems
Medication Assisted Treatment
Disability After Traumatic Brain Injury among Hispanic Children
Evaluating the Effectiveness of Social Work Interventions:
Mental and Behavioral Health Services
How To Design a Clinical Trial
Predictors of study retention in drug abuse treatment trials
Differences in Treatment Outcome and Current Cognitive and Behavioral Functioning of Individuals Who Received Ibogaine-Assisted Treatment for a SUD Alan.
US Census Data Ortman, Jennifer M., Victoria A. Velkoff, and Howard Hogan. An Aging Nation: The Older Population in the United States, Current Population.
Drugs and Neuron Communication
Levels of Care Continuum of Care ASAM Patient Placement Criteria (PPC)
6% of adults had used one or more illicit drugs in last 12 months.
Medication-Assisted Therapy at Coleman Profession Services
Current Mental Health Care Systems
Resolving outcome disparities in depression for minority primary care patients with collaborative care management Kurt B. Angstman, MS MD Associate Professor.
White River Junction, Vermont VA Outcomes Group REAP
McLean Hospital Division of Alcohol and Drug Abuse
Emily Patry, BS The Miriam Hospital, Providence, RI
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
Believed discrimination occurred because of their:
Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2,
Community Care Teams Carl Schiessl, Director, Regulatory Advocacy
2017 State of C.O.R.E. performance measures.
2017 New Mexico Substance Abuse Epidemiology Profile
Treatments for Addiction
Developing an Effective Assisted Outpatient Treatment Program
Bronx Community Health Dashboard: Drug Abuse and Opioids Created: 5/18/2017 Last Updated: 10/23/2017 See last slide for more information.
Bidirectional Association Between Homelessness and Incarceration Among Veterans Participating in HUD-VASH Dennis Culhane, PhD.
Maintenance Treatment
Receipt of Medication Treatment after Nonfatal Overdose Among Emerging Adults Sarah M. Bagley, MD, MSc Assistant Professor of Medicine and Pediatrics,
treatment service Authors names
W.H.O. DEFINITION OF PRIMARY CARE
Comparative Effectiveness of Alcohol and Drug Treatment in HIV Infected Veterans Kevin L. Kraemer, MD, MSc Professor of Medicine and Clinical & Translational.
Preliminary Outcomes of the Texas Access to Recovery Project
Michael C. White, MCJ
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Brett Harris, DrPH AMERSA Conference November 2-4, 2017
Strategic Initiatives to Address Opioid Overdose & Addiction
Medically assisted treatment
Can be personalized to individual group needs.
Presentation transcript:

The relationship between incarceration and opioid addiction treatment Daniel P. Riggins Mentor: Aaron D. Fox M.D.

X Background – Cycle of Addiction and Incarceration: Incarceration Treatment? Detox? Relapse X - In 2010, more than 900,000 Americans met criteria for an opioid use disorder (0.3%) - Up to 1/3 of heroin users are incarcerated annually - Fewer than 1% of incarcerated heroin users receive one of these medications in the United States - Opioids accounting for a 129x increased risk in the first two weeks of release - Up to ¾ of prisoners with opioid use disorders relapse to illicit opioid use within 6 months of prison release Release

Background – Opioid replacement therapy with buprenorphine (bupe): Opioid derivative with mixed effects at opioid receptors Can be used to treat withdrawal, for titrated cessation, or for long-term maintenance. Advantages over methadone: Can be self-administered at home Low potential for abuse Less stigmatized

Study Objectives: To determine if criminal justice status is associated with buprenorphine treatment outcomes To determine if buprenorphine treatment is associated with lower rates of incarceration

Methods: Design: Secondary analysis longitudinal cohort study Setting: Buprenorphine, HIV Evaluation and Support Collaborative (BHIVES) 10 community and hospital-based care centers Population: HIV+ primary care patients Initiating buprenorphine treatment for opioid use disorder Data collection: Surveys (baseline, quarterly x 1 yr) Chart review (at study completion)

Methods - Variables: Recent incarceration (collected from surveys) Treatment retention (determined from chart review) Independent Variable Dependent Variable Serve as both independent and dependent variables

Methods - Variables: Recent incarceration Treatment retention Independent Variable Subject reported any incarceration in 30 days before baseline interview Dependent Variable Serve as both independent and dependent variables

Results – Population Characteristics: Not recently incarcerated (N = 266) Recently incarcerated (N = 40) P-value Age, mean years +/- SD 44.6 +/- 8.4 44.4 +/- 9.3 P = 0.93 Race/Ethnicity, % (N): White 22.9% (61) 20.0% (8) P = 0.68 Black 50% (133) 57.5% (23) P = 0.38 Hispanic 22.2% (59) P = 0.76 Other 3.4% (9) 2.5% (1) P = 1.00 Male, % (N) 67.3% (179) 67.5% (27) P = 0.98 Homeless, % (N) 22.6% (60) 40.0% (16) P = 0.02 Employed, % (N) 27.8% (74) 10% (4) Ever diagnosed with mental illness, % (N) 53.2% (140) 73.7% (28) Serve as both independent and dependent variables

Methods - Variables: Recent incarceration Treatment retention Independent Variable Subject reported any incarceration in 30 days before baseline interview Dependent Variable Number of consecutive quarters subject received buprenorphine treatment Serve as both independent and dependent variables

Do people reporting recent incarceration at baseline have lower retention rates in bupe treatment? Chi squared analysis

Subject received buprenorphine treatment for ≥ 1 quarter (yes/no) Methods - Variables: Recent incarceration Treatment retention Independent Variable Subject received buprenorphine treatment for ≥ 1 quarter (yes/no) Dependent Variable Subject reported any incarceration in 30 days before each quarterly interview Serve as both independent and dependent variables

Do people retained on bupe treatment have lower rates of incarceration? Chi-squared analysis * Is p < 0.05; ** is p < 0.01

Conclusions: Recent incarceration was associated with: homelessness, unemployment, mental illness Over time, those with recent incarceration seemed to have lower treatment retention Over time, those retained in treatment had lower rates of incarceration Chi-squared analysis

Implications: Individuals with recent incarceration before starting therapy may need additional support to maintain retention in treatment Buprenorphine maintenance therapy may help decrease incarceration rates for individuals with opioid use disorder - Peer mentorship might be one effective source of support - We intend to do multi-variable, time-adjusted analysis

Acknowledgments: Linda Weiss and Bert Chantarat from the New York Academy of Medicine for providing data Yuming Ning for preparing the dataset Aaron Fox for providing mentorship and allowing me to shadow at the Transitions Clinic Ellie Schoenbaum for coordinating student research at Einstein Chi-squared analysis

If we have time…

What is the profile of people with each criminal justice status? Those who have ever been incarcerated are more likely to: Be male Not have a high school diploma Have a lower composite score of addiction severity Have ever injected drugs Have ever used methadone and marijuana Have been using opioids longer Have overdosed more frequently Have been treated for drug abuse more frequently

What is the profile of people with each criminal justice status? Those who have recently been incarcerated are more likely to: Live alone Be homeless Be unemployed Have a diagnosed mental illness Have a lower composite score for addiction severity Have ever injected drugs Have ever used heroin Been treated for drug abuse more frequently

What is the profile of people with each criminal justice status? Those on parole or probation are more likely to: Not speak English as their primary language Be male Have a lower composite score for addiction severity Have ever injected drugs Have ever used heroin and methadone Have been using opioids longer Have overdosed more frequently Have been treated for drug abuse more frequently